Filing Flows › Health Care › RenovoRx (RNXT)
RenovoRx (RNXT) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · RenovoRx (RNXT) Q3 2026 earnings results →
Q3 2026 Revenue up 301% year over year to $1.1M · 342¢ of every $1 of revenue lost · operating margin -303.6%
RenovoRx made $1.1M in Q3 2026 (+301% Y/Y). Operating margin -303.6%, net loss $3.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.1M in Q3 2026, up 301% year over year and up 17% from the previous quarter.
Gross margin was 82.4%, up 2.3 points from Q3 2025. Operating costs exceeded revenue by $3.2M, an operating margin of -303.6%. Operating expenses grew 21% against revenue growth of 301%. The fastest-growing cost line was SG&A (+66%). The quarter ended with a net loss of $3.6M, wider than the previous quarter's $2.9M loss.
Operating cash flow was −$2.5M. Non-cash charges added back $5K of depreciation and $469K of share-based compensation. Working capital and other items added $634K. Capital expenditures of $19K exceeded it, leaving free cash flow of −$2.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $1.1M | +301% | -303.6% | −$3.6M | −$2.5M |
| Q2 2026 | 10-Q | Aug 13, 2026 | $909K | +115% | -368.4% | −$2.9M | −$2.9M |
| Q1 2026 | 10-Q | May 14, 2026 | $563K | +186% | -616.2% | −$3.5M | −$3.7M |
| Q4 2025 | 10-K | Mar 30, 2026 | $238K | — | n/m | −$2.9M | −$3.0M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $266K | — | n/m | −$2.9M | −$2.3M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $422K | — | -634.6% | −$2.9M | −$2.3M |
| Q1 2025 | 10-Q | May 15, 2025 | $197K | — | n/m | −$2.4M | −$3.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About RenovoRx
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company commercializing RenovoCath®, a novel, FDA-cleared device for local drug delivery designed to address significant unmet medical needs, with a focus on difficult-to-treat tumors. The Company is also evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath using RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform as a novel drug-device product candidate for locally advanced pancreatic cancer. RenovoRx’s patented TAMP™ platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, potentially improving safety, tolerance, and efficacy while minimizing the toxicities associated with systemic intravenous therapy.
In its own words, from its 8-K, filed Nov 5, 2026.
RenovoRx against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +301% against the peers' median +5%. Operating margin: -303.6% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RNXT RenovoRx | Q3 2026 | $1.1M | +301% | -303.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: RenovoRx 10-Q on SEC EDGAR · CIK 1574094 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns RNXT and who is buying
More on RNXT
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results